ヒトマイクロバイオーム市場は、研究の増加、技術の進歩、健康と疾患におけるマイクロバイオームの役割に対する意識の高まりにより、予測期間中に38億ドルに達すると予想されています。主な動向は、マイクロバイオームベースの治療法、診断薬、プロバイオティクスの拡大であり、製薬会社やベンチャーキャピタリストからの多額の投資を受けています。市場は、胃腸の健康、代謝障害、免疫調節、メンタルヘルスなど、幅広い領域を網羅しています。市場における高いフェーズは、マイクロバイオーム治療薬、特に糞便微生物移植(FMT)とマイクロバイオーム調節薬の開発です。ヒトマイクロバイオーム市場は、計り知れない可能性を秘めています。これらの障害を克服し、ヒトマイクロバイオームの治療および診断の可能性を完全に実現し、最終的には革新的なヘルスケアソリューションと個別化医療アプローチにつながるためには、科学者、臨床医、および業界の利害関係者間の継続的な研究と協力が不可欠です。
目次
Table of Content
1. Executive Summary
1.1. Regional Market Share
1.2. Business Trends
1.3. Human Microbiome Market: COVID-19 Outbreak
1.4. Regional Trends
1.5. Segmentation Snapshot
2. Research Methodology
2.1. Research Objective
2.2. Research Approach
2.3. Data Sourcing and Methodology
2.4. Primary Research
2.5. Secondary Research
2.5.1. Paid Sources
2.5.2. Public Sources
2.6. Market Size Estimation and Data Triangulation
3. Market Characteristics
3.1. Market Definition
3.2. Human Microbiome Market: COVID-19 Impact
3.3. Key Segmentations
3.4. Key Developments
3.5. Allied Industry Data
4. Human Microbiome Market - Industry Insights
4.1. Industry Segmentation
4.2. COVID-19 overview of world economy
4.3. Industry Ecosystem Channel Analysis
4.4. Innovation & Sustainability
5. Macroeconomic Indicators
6. Recent Developments
7. Market Dynamics
7.1. Introduction
7.2. Growth Drivers
7.3. Market Opportunities
7.4. Market Restraints
7.5. Market Trends
8. Risk Analysis
9. Market Analysis
9.1. Porter's Five Forces
9.2. PEST Analysis
9.2.1. Political
9.2.2. Economic
9.2.3. Social
9.2.4. Technological
10. Human Microbiome Market
10.1. Overview
10.2. Historical Analysis (2018-2022)
10.2.1. Market Size, Y-o-Y Growth (%) and Market Forecast
11. Human Microbiome Market Size & Forecast 2024A-2034F
11.1. Overview
11.2. Key Findings
11.3. Market Segmentation
11.3.1. By Product
11.3.1.1. Drugs
11.3.1.1.1. By Value (USD Million) 2024A-2034F
11.3.1.1.2. Market Share (%) 2024A-2034F
11.3.1.1.3. Y-o-Y Growth (%) 2024A-2034F
11.3.1.2. Diagnostic Tests
11.3.1.2.1. By Value (USD Million) 2024A-2034F
11.3.1.2.2. Market Share (%) 2024A-2034F
11.3.1.2.3. Y-o-Y Growth (%) 2024A-2034F
11.3.1.3. Probiotics
11.3.1.3.1. By Value (USD Million) 2024A-2034F
11.3.1.3.2. Market Share (%) 2024A-2034F
11.3.1.3.3. Y-o-Y Growth (%) 2024A-2034F
11.3.1.4. Prebiotics
11.3.1.4.1. By Value (USD Million) 2024A-2034F
11.3.1.4.2. Market Share (%) 2024A-2034F
11.3.1.4.3. Y-o-Y Growth (%) 2024A-2034F
11.3.1.5. Others
11.3.1.5.1. By Value (USD Million) 2024A-2034F
11.3.1.5.2. Market Share (%) 2024A-2034F
11.3.1.5.3. Y-o-Y Growth (%) 2024A-2034F
11.3.2. By Application
11.3.2.1. Therapeutics
11.3.2.1.1. By Value (USD Million) 2024A-2034F
11.3.2.1.2. Market Share (%) 2024A-2034F
11.3.2.1.3. Y-o-Y Growth (%) 2024A-2034F
11.3.2.2. Diagnostics
11.3.2.2.1. By Value (USD Million) 2024A-2034F
11.3.2.2.2. Market Share (%) 2024A-2034F
11.3.2.2.3. Y-o-Y Growth (%) 2024A-2034F
11.3.2.3. Others
11.3.2.3.1. By Value (USD Million) 2024A-2034F
11.3.2.3.2. Market Share (%) 2024A-2034F
11.3.2.3.3. Y-o-Y Growth (%) 2024A-2034F
11.3.3. By Disease
11.3.3.1. Infectious Disease
11.3.3.1.1. By Value (USD Million) 2024A-2034F
11.3.3.1.2. Market Share (%) 2024A-2034F
11.3.3.1.3. Y-o-Y Growth (%) 2024A-2034F
11.3.3.2. Gastrointestinal Disease
11.3.3.2.1. By Value (USD Million) 2024A-2034F
11.3.3.2.2. Market Share (%) 2024A-2034F
11.3.3.2.3. Y-o-Y Growth (%) 2024A-2034F
11.3.3.3. Endocrine & Metabolic Disorders
11.3.3.3.1. By Value (USD Million) 2024A-2034F
11.3.3.3.2. Market Share (%) 2024A-2034F
11.3.3.3.3. Y-o-Y Growth (%) 2024A-2034F
11.3.3.4. Cancer
11.3.3.4.1. By Value (USD Million) 2024A-2034F
11.3.3.4.2. Market Share (%) 2024A-2034F
11.3.3.4.3. Y-o-Y Growth (%) 2024A-2034F
11.3.3.5. Others Diseases
11.3.3.5.1. By Value (USD Million) 2024A-2034F
11.3.3.5.2. Market Share (%) 2024A-2034F
11.3.3.5.3. Y-o-Y Growth (%) 2024A-2034F
11.3.4. By Type
11.3.4.1. Fecal Microbiota Transplantation (FMT)
11.3.4.1.1. By Value (USD Million) 2024A-2034F
11.3.4.1.2. Market Share (%) 2024A-2034F
11.3.4.1.3. Y-o-Y Growth (%) 2024A-2034F
11.3.4.2. Peptide
11.3.4.2.1. By Value (USD Million) 2024A-2034F
11.3.4.2.2. Market Share (%) 2024A-2034F
11.3.4.2.3. Y-o-Y Growth (%) 2024A-2034F
11.3.4.3. Live Biotherapeutic Product
11.3.4.3.1. By Value (USD Million) 2024A-2034F
11.3.4.3.2. Market Share (%) 2024A-2034F
11.3.4.3.3. Y-o-Y Growth (%) 2024A-2034F
11.3.4.4. Others
11.3.4.4.1. By Value (USD Million) 2024A-2034F
11.3.4.4.2. Market Share (%) 2024A-2034F
11.3.4.4.3. Y-o-Y Growth (%) 2024A-2034F
11.3.5. By End-Users
11.3.5.1. Hospitals & Clinics
11.3.5.1.1. By Value (USD Million) 2024A-2034F
11.3.5.1.2. Market Share (%) 2024A-2034F
11.3.5.1.3. Y-o-Y Growth (%) 2024A-2034F
11.3.5.2. Pharmaceutical & Biotechnology Companies
11.3.5.2.1. By Value (USD Million) 2024A-2034F
11.3.5.2.2. Market Share (%) 2024A-2034F
11.3.5.2.3. Y-o-Y Growth (%) 2024A-2034F
11.3.5.3. Food Businesses
11.3.5.3.1. By Value (USD Million) 2024A-2034F
11.3.5.3.2. Market Share (%) 2024A-2034F
11.3.5.3.3. Y-o-Y Growth (%) 2024A-2034F
11.3.5.4. Others
11.3.5.4.1. By Value (USD Million) 2024A-2034F
11.3.5.4.2. Market Share (%) 2024A-2034F
11.3.5.4.3. Y-o-Y Growth (%) 2024A-2034F
12. North America Human Microbiome Market Size & Forecast 2024A-2034F
12.1. Overview
12.2. Key Findings
12.3. Market Segmentation
12.3.1. By Product
12.3.2. By Application
12.3.3. By Disease
12.3.4. By Type
12.3.5. By End-User
12.4. Country
12.4.1. United States
12.4.2. Canada
13. Europe Human Microbiome Market Size & Forecast 2024A-2034F
13.1. Overview
13.2. Key Findings
13.3. Market Segmentation
13.3.1. By Product
13.3.2. By Application
13.3.3. By Disease
13.3.4. By Type
13.3.5. By End-User
13.4. Country
13.4.1. Germany
13.4.2. United Kingdom
13.4.3. France
13.4.4. Italy
13.4.5. Spain
13.4.6. Russia
13.4.7. Rest of Europe (BENELUX, NORDIC, Hungary, Turkey & Poland)
14. Asia-Pacific Human Microbiome Market Size & Forecast 2024A-2034F
14.1. Overview
14.2. Key Findings
14.3. Market Segmentation
14.3.1. By Product
14.3.2. By Application
14.3.3. By Disease
14.3.4. By Type
14.3.5. By End-User
14.4. Country
14.4.1. India
14.4.2. China
14.4.3. South Korea
14.4.4. Japan
14.4.5. Rest of APAC
15. Middle East and Africa Human Microbiome Market Size & Forecast 2024A-2034F
15.1. Overview
15.2. Key Findings
15.3. Market Segmentation
15.3.1. By Product
15.3.2. By Application
15.3.3. By Disease
15.3.4. By Type
15.3.5. By End-User
15.4. Country
15.4.1. Israel
15.4.2. GCC
15.4.3. North Africa
15.4.4. South Africa
15.4.5. Rest of Middle East and Africa
16. Latin America Human Microbiome Market Size & Forecast 2024A-2034F
16.1. Overview
16.2. Key Findings
16.3. Market Segmentation
16.3.1. By Product
16.3.2. By Application
16.3.3. By Disease
16.3.4. By Type
16.3.5. By End-User
16.4. Country
16.4.1. Mexico
16.4.2. Brazil
16.4.3. Rest of Latin America
17. Competitive Landscape
17.1. Company market share, 2021
17.2. Key player overview
17.3. Key stakeholders
18. Company Profiles
18.1. Vedanta Biosciences
18.1.1. Company Overview
18.1.2. Financial Overview
18.1.3. Key Product; Analysis
18.1.4. Company Assessment
18.1.4.1. Product Portfolio
18.1.4.2. Key Clients
18.1.4.3. Market Share
18.1.4.4. Recent News & Development (Last 3 Yrs.)
18.2. Seres Therapeutics
18.3. Second Genome
18.4. Rebiotix
18.5. Microbiome Insights
18.6. 4D Pharma
18.7. Synlogic
18.8. Microbiome Therapeutics
18.9. AOBiome
18.10. uBiome
18.11. Finch Therapeutics
18.12. Seed Health
18.13. Viome
18.14. Holobiome
18.15. Axial Biotherapeutics
18.16. Other Prominent Players
19. Appendix
20. Consultant Recommendation
